Here's why the Patrys (ASX: PAB) share price is climbing 13% today

This small-cap ASX share revealed some exciting news today.

| More on:
A medical researcher in a white coat holds laboratory equipment and smiles.

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Patrys Limited (ASX: PAB) share price is starting the week on a strong note. This comes after the therapeutic antibody development company announced new data from non-clinical studies of its cancer-fighting antibody, PAT-DX3.

Patrys is developing a full-sized immunoglobulin G (IgG) antibody and humanised version of a smaller deoxymab antibody fragment to treat cancers through DNA.

During morning trade, the company's shares are up 13.73% to 5.8 cents.

What did Patrys announce?

In a statement to the ASX, Patrys advised that PAT-DX3 is able to cross the blood-brain barrier (BBB) in an animal model of primary brain cancer. This includes the most aggressive type of cancer, glioblastoma multiforme (GBM).

The company noted that previous studies showed a smaller antibody fragment, PAT-DX1, can cross the BBB. However, this is the first time a full-sized deoxymab (PAT-DX3) has done so.

The company is now planning follow-up studies to compare the effects of both PAT-DX1 and PAT-DX3. Patrys will look at tumour reduction and survival in a range of primary and secondary brain cancer models.

In addition, PAT-DX3 is also being tested to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells.

Patrys CEO and managing director Dr James Campbell said:

We are very excited by this new discovery that opens up a range of development and partnering opportunities for Patrys around PAT-DX3.

As PAT-DX3 shares a common mechanism of action with PAT-DX1, it is expected that it will also localise to both primary and secondary tumours in the brain and selectively kill cancer cells by blocking their DNA Damage Repair (DDR) systems. While Patrys remains focused on preparing for its first-in-human study of PAT-DX1, it is clear that PAT-DX3 is a valuable addition to the company's deoxymab antibody platform.

About the Patrys share price

During the last 12 months, the Patrys share price has accelerated by more than 380% and more than 141% in 2021. It's worth noting the company's share price is nearing its 52-week high of 6.3 cents achieved late last month.

Patrys has a market capitalisation of roughly $105 million, with approximately 1.8 billion shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough start to the week this Monday.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Broker Notes

Guess which popular ASX 200 stock Bell Potter just downgraded

Let's see what the broker is saying on this blue chip.

Read more »

Crude oil barrels rocketing.
ETFs

Why did the BetaShares Crude Oil ETF just spike 4%?

This ETF is attracting buyers in today's seller's market.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why BWP, Metcash, Resolute Mining, and SHAPE shares are pushing higher today

These shares are starting the week on a positive note. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Adairs, ANZ, Aurelia Metals, and Pilbara Minerals shares are falling today

These shares are having a tough start to the week in the red. But why?

Read more »

Miner standing in a mine site with his arms crossed.
Broker Notes

Up 41% in 2025, does Macquarie think Lynas Rare Earths shares have peaked?

The company is up nearly 400% in 5 years.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Share Market News

How far could equity markets fall following the US' attack on Iran?

If oil prices rise, it could be bad news for investors.

Read more »